ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 142 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $193 | -82.3% | 17,219 | -66.2% | 0.00% | -100.0% |
| Q2 2023 | $1,089 | +2.5% | 50,904 | +93.9% | 0.00% | – |
| Q1 2023 | $1,062 | -55.2% | 26,250 | -48.4% | 0.00% | -100.0% |
| Q4 2022 | $2,368 | -99.9% | 50,899 | +12.2% | 0.00% | -66.7% |
| Q3 2022 | $2,353,000 | +758.8% | 45,368 | +682.6% | 0.00% | – |
| Q2 2022 | $274,000 | -74.3% | 5,797 | -61.3% | 0.00% | -100.0% |
| Q1 2022 | $1,066,000 | -71.5% | 14,970 | -70.1% | 0.00% | 0.0% |
| Q4 2021 | $3,744,000 | +189.6% | 50,076 | +120.0% | 0.00% | 0.0% |
| Q3 2021 | $1,293,000 | +161.2% | 22,757 | +103.0% | 0.00% | – |
| Q2 2021 | $495,000 | -57.4% | 11,210 | -52.4% | 0.00% | -100.0% |
| Q1 2021 | $1,161,000 | +11.2% | 23,537 | -5.0% | 0.00% | 0.0% |
| Q4 2020 | $1,044,000 | -13.1% | 24,770 | -5.6% | 0.00% | 0.0% |
| Q3 2020 | $1,202,000 | +33.0% | 26,231 | +45.9% | 0.00% | 0.0% |
| Q2 2020 | $904,000 | +19.1% | 17,976 | +21.7% | 0.00% | 0.0% |
| Q1 2020 | $759,000 | -74.6% | 14,765 | -69.5% | 0.00% | -50.0% |
| Q4 2019 | $2,988,000 | +37.3% | 48,370 | +33.4% | 0.00% | +100.0% |
| Q3 2019 | $2,177,000 | -29.6% | 36,255 | -1.1% | 0.00% | -50.0% |
| Q2 2019 | $3,093,000 | -42.4% | 36,640 | -34.8% | 0.00% | -50.0% |
| Q1 2019 | $5,370,000 | +575.5% | 56,224 | +400.5% | 0.00% | +300.0% |
| Q4 2018 | $795,000 | -67.4% | 11,234 | -60.6% | 0.00% | -50.0% |
| Q3 2018 | $2,438,000 | +285.8% | 28,533 | +423.1% | 0.00% | +100.0% |
| Q2 2018 | $632,000 | -3.4% | 5,455 | -32.6% | 0.00% | – |
| Q1 2018 | $654,000 | -58.7% | 8,097 | -70.0% | 0.00% | -100.0% |
| Q4 2017 | $1,582,000 | +26.9% | 26,960 | +1.2% | 0.00% | 0.0% |
| Q3 2017 | $1,247,000 | +15.8% | 26,635 | -11.1% | 0.00% | 0.0% |
| Q2 2017 | $1,077,000 | -41.0% | 29,960 | -49.4% | 0.00% | -50.0% |
| Q1 2017 | $1,824,000 | +399.7% | 59,264 | +444.0% | 0.00% | – |
| Q4 2016 | $365,000 | +1638.1% | 10,894 | +1265.2% | 0.00% | – |
| Q3 2016 | $21,000 | +133.3% | 798 | +112.8% | 0.00% | – |
| Q2 2016 | $9,000 | -86.2% | 375 | -83.3% | 0.00% | – |
| Q1 2016 | $65,000 | +400.0% | 2,244 | +487.4% | 0.00% | – |
| Q4 2015 | $13,000 | -92.7% | 382 | -92.2% | 0.00% | – |
| Q3 2015 | $177,000 | +941.2% | 4,925 | +1238.3% | 0.00% | – |
| Q2 2015 | $17,000 | -22.7% | 368 | -50.2% | 0.00% | – |
| Q1 2015 | $22,000 | -48.8% | 739 | -11.2% | 0.00% | – |
| Q4 2014 | $43,000 | -97.1% | 832 | -97.8% | 0.00% | -100.0% |
| Q3 2014 | $1,495,000 | -49.5% | 38,348 | -44.3% | 0.00% | -66.7% |
| Q2 2014 | $2,962,000 | -5.6% | 68,888 | -14.4% | 0.00% | -25.0% |
| Q1 2014 | $3,138,000 | -24.1% | 80,459 | -47.4% | 0.00% | 0.0% |
| Q4 2013 | $4,132,000 | -9.4% | 153,043 | -26.2% | 0.00% | -20.0% |
| Q3 2013 | $4,560,000 | +43.4% | 207,277 | +15.4% | 0.01% | +25.0% |
| Q2 2013 | $3,180,000 | – | 179,569 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |